高风险计划为乳腺癌风险较高的女性提供监测/降低风险的建议。本研究评估了诊断时参与高风险监测计划对乳腺癌临床病理特征的影响。作者的高风险计划（高风险队列 [HRC]）对从 1 月份起诊断为乳腺癌的女性进行了跟踪调查确定了 2015 年至 2021 年 6 月期间在纪念斯隆·凯特琳癌症中心（MSK；一般队列 [GC]）接受乳腺癌手术的女性一般人群，并将其与同期进行比较。收集患者和肿瘤因子。对两个队列以及具有已知 BRCA 突变家族史的女性子集之间的临床病理特征进行了比较。该研究对 HRC 中的 255 名女性与 GC 中的 9342 名女性进行了比较。与 GC 患者相比，HRC 患者年龄稍大，且更有可能是白人且有家族史。 HRC 患者也更有可能出现 DCIS（41% vs 23%；p < 0.001），具有较小的侵袭性肿瘤（pT1：100% vs 77%；p < 0.001），并且 pN0（95% vs 81%；p < 0.001)。 HRC 患者具有更多侵袭性三阴性肿瘤 (p = 0.01)，并且接受较少的腋窝手术 (p < 0.001)、全身治疗 (p < 0.001) 和放射治疗 (p = 0.002)。在已知 BRCA 突变的女性中，HRC 中接受筛查的 12 个月内，显着更多女性接受了乳房 X 光检查（75 % vs 40 %；p < 0.001）或磁共振成像（MRI：82 % vs 9.9 %；p < 0.001）。诊断。参加高风险筛查计划的女性在早期阶段就被诊断出疾病，因此与诊断时到癌症中心就诊的女性相比，需要较少强度的乳腺癌治疗。识别高危女性并实施加强监测方案对于改善结果至关重要。© 2024。外科肿瘤学会。

High-risk programs provide recommendations for surveillance/risk reduction for women at elevated risk for breast cancer development. This study evaluated the impact of high-risk surveillance program participation on clinicopathologic breast cancer features at the time of diagnosis.Women followed in the authors' high-risk program (high-risk cohort [HRC]) with a diagnosis of breast cancer from January 2015 to June 2021 were identified and compared with the general population of women undergoing breast cancer surgery at Memorial Sloan Kettering Cancer Center (MSK; general cohort [GC]) during the same period. Patient and tumor factors were collected. Clinicopathologic features were compared between the two cohorts and in a subset of women with a family history of known BRCA mutation.The study compared 255 women in the HRC with 9342 women in the GC. The HRC patients were slightly older and more likely to be white and have family history than the GC patients. The HRC patients also were more likely to present with DCIS (41 % vs 23 %; p < 0.001), to have smaller invasive tumors (pT1: 100 % vs 77 %; p < 0.001), and to be pN0 (95 % vs 81 %; p < 0.001). The HRC patients had more invasive triple-negative tumors (p = 0.01) and underwent less axillary surgery (p < 0.001), systemic therapy (p < 0.001), and radiotherapy (p = 0.002). Among those with a known BRCA mutation, significantly more women in the HRC underwent screening mammography (75 % vs 40 %; p < 0.001) or magnetic resonance imaging (MRI: 82 % vs 9.9 %; p < 0.001) in the 12 months before diagnosis.Women followed in a high-risk screening program have disease diagnosed at an earlier stage and therefore require less-intensive breast cancer treatment than women presenting to a cancer center at the time of diagnosis. Identification of high-risk women and implementation of increased surveillance protocols are vital to improving outcomes.© 2024. Society of Surgical Oncology.